Business
INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 9, 2022 /PRNewswire/ -- INVO
About this update from Invo Fertility, Inc.
[{"type":"text","content":"Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET\nSARASOTA, Fla., May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Monday, May 16, 2022. The Company has scheduled a conference call that same day, Monday, May 16, 2022, at 4:30 pm ET, to review the results.\n\n \n \n \n \n \n \n\n \nFirst Quarter 2022 Conference Call Details\nDate and Time: Monday, May 16, 2022 at 4:30 pm ET\nCall-in Information: Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751.\nLive Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ or https://app.webinar.net/6XQVP1XJjRA.\nReplay: A teleconference replay of the call will be available through May 23, 2022, at 877-344-7529 or 412-317-0088, replay access code # 4725753. A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days. \nAbout INVO Bioscience\nWe are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology (\"ART\") marketplace by making fertility care accessible and inclusive to people around the world. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as \"IVC\", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertili...